[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338390-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-338390-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","real-world-genome-profiling-in-japanese-patients-with-pancreatic-ductal-adenocarcinoma-focusing-on-hrd-implications","Real-world genome profiling in Japanese patients with pancreatic ductal adenocarcinoma focusing on HRD implications","","Pancreatic ductal adenocarcinoma poses major clinical challenges due to high mortality, prompting analysis of real-world comprehensive genome profiling (CGP) outcomes in Japanese patients. This retrospective observational study evaluated 2568 PDAC patients tested between June 2019 and December 2021 using nationwide C-CAT data, emphasizing differences in gene detection across tissue versus liquid assays and the clinical implications for homologous recombination deficiency (HRD). Tissue testing showed higher abnormal detection rates, with HRD-related alterations in 23% of patients.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/real-world-genome-profiling-in-japanese-patients-with-pancreatic-ductal-adenocarcinoma-focusing-on-hrd-implications/338390/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/real-world-genome-profiling-in-japanese-patients-with-pancreatic-ductal-adenocarcinoma-focusing-on-hrd-implications/338390.png","ImageObject",300,407,{"name":42,"@type":43},"Eden","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of the study on CGP in PDAC patients?","Question",{"text":63,"@type":64},"To analyze real-world comprehensive genome profiling data in Japanese PDAC patients, focusing on differences in gene detection rates among CGP panels and the implications for HRD status.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many PDAC patients were included, and when were they tested?",{"text":68,"@type":64},"A total of 2568 PDAC patients were enrolled, with CGP performed between June 2019 and December 2021.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find about HRD-related gene alterations?",{"text":72,"@type":64},"HRD-related gene alterations were detected in 23% of patients, with BRCA1 and BRCA2 mutations accounting for 0.9% and 2.9% respectively.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338390,1790536066,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","DOI: 10. 1111/cas.16329  \nOR I G I NAL ART I C L E  \nReal-world genome profiling in Japanese patients with pancreatic ductal adenocarcinoma focusing on HRD implications  \nToshifumi Doi1,2  | Takeshi Ishikawa1,2,3  | Tomoki Sakakida1,2  | Junichiro Itani1,2 | Daiki Sone1,2 | Ryuichi Morita1,2 | Seita Kataoka1 | Hayato Miyake1 | Yuya Seko1 | Kanji Yamaguchi1 | Michihisa Moriguchi1 | Yoshio Sogame1 | Hideyuki Konishi1 | Kyoko Murashima2 | Masahiro Iwasaku2,4 | Koichi Takayama2,3,4 | Yoshito Itoh1  \n1Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan  \n2Cancer Genome Medical Center, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan 3 Department of Medical Oncology Unit, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan 4Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan  \nCorrespondence  \nTakeshi Ishikawa, Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-dori Hirokojiagaru, Kamigyo-ku, Kyoto 602-8566, Japan.  \nEmail: [iskw-t@koto.kpu-m.ac.jp](iskw-t@koto.kpu-m.ac.jp)  \nAbstract  \nPancreatic ductal adenocarcinoma (PDAC) poses significant challenges due to its high mortality, making it a critical area of research. This retrospective observational study aimed to analyze real-world data from comprehensive genome profiling (CGP) of Japanese patients with PDAC, mainly focusing on differences in gene detection rates among panels and the implications for homologous recombination deficiency (HRD) status. This study enrolled 2568 patients with PDAC who had undergone CGP between June 2019 and December 2021 using data from the nationwide Center for Cancer Genomics and Advanced Therapeutics database. Two types of CGP assays (tissue and liquid biopsies) were compared and a higher detection rate of genetic abnormalities in tissue specimens was revealed. HRD-related gene alterations were detected in 23% of patients, with BRCA1/2 mutations accounting for 0.9% and 2.9% of patients, respectively. Treatment outcome analysis indicated that patients with BRCA1/2 mutations had a longer time to treatment discontinuation with FOLFIRINOX than gemcitabine plus nab-paclitaxel as first-line therapy (9. 3 vs. 5.6 months, p = 0.028) . However, no significant differences were observed in the treatment response among the other HRD-related genes. Logistic regression analysis identified younger age and family history of breast, prostate, and ovarian cancers as predictive factors for HRDrelated gene alterations. Despite the lack of progression-free survival data and the inability to discriminate between germline and somatic mutations, this study provides valuable insights into the clinical implications of CGP in Japanese patients with PDAC.  \nAbbreviations: C-CAT, Center for Cancer Genomics and Advanced Therapeutics; CGP, comprehensive genome profiling; CHIP, clonal hematopoiesis of indeterminate potential; CI, confidence interval; ctDNA, circulating tumor DNA; DCR, disease control rate; ECOG-PS, ECOG performance status; F1, FoundationOne CDx; F1L, FoundationOne Liquid CDx; FFX, FOLFIRINOX; GI, gastrointestinal; GnP, gemcitabine plus nab-paclitaxel; HRD, homologous recombination deficiency; HRR, homologous recombination repair; NCC, OncoGuide NCCOncopanel System; OR, odds ratio; ORR, overall response rate; OS, overall survival time; PARP, poly(ADP-ribose)polymerase; PDAC, pancreatic ductal adenocarcinoma; PFS, progression-free survival; TTD, time to treatment discontinuation.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2024 The Author(s) . Cancer Sci","cbCairYkeJzjzUXO","https://ap.wps.com/l/cbCairYkeJzjzUXO","pdf",5311905,11,"English","# Abstract\n## Introduction\n## Methods and Study Design\n## Results and Findings\n## Discussion and Clinical Implications","[{\"question\":\"What is the main goal of the study on CGP in PDAC patients?\",\"answer\":\"To analyze real-world comprehensive genome profiling data in Japanese PDAC patients, focusing on differences in gene detection rates among CGP panels and the implications for HRD status.\"},{\"question\":\"How many PDAC patients were included, and when were they tested?\",\"answer\":\"A total of 2568 PDAC patients were enrolled, with CGP performed between June 2019 and December 2021.\"},{\"question\":\"What did the study find about HRD-related gene alterations?\",\"answer\":\"HRD-related gene alterations were detected in 23% of patients, with BRCA1 and BRCA2 mutations accounting for 0.9% and 2.9% respectively.\"}]","Real-world genome profiling in Japanese patients with pancreatic ductal adenocarcinoma focusing on HRD implications | PDF",1790023445,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4112262e0a7800adefa4a5302b359a8b.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a62dd9d4bf2be461709e8a8a24100311.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a403d6bf96fc89302b9d8b2c5e357fc5.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d991e3dc9237a4ef3a719389461de7d8.webp",980,1287]